Endocrine Complications and Paraneoplastic Syndromes

Abstract

Overview Transformation of normal cells results in activation and/or suppression of a number of hormonally active genes, resulting in ectopic humoral paraneoplastic syndromes. Treatment of cancer also results in a number of endocrine or metabolic abnormalities, most of which are related to hormone deficiency or drug‐related toxicity. Targeted therapy may disrupt signaling pathways involved in endocrine function, and immunotherapy has led to autoimmune endocrine dysfunctions. This article will outline ectopic endocrine paraneoplastic syndromes and the major endocrine toxicities of antineoplastic therapy.